The future is bright, the future is CGT

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lung-I, covering:

• His take on the different models of healthcare he has seen globally, and the value they do and don’t deliver to patients
• The access, and infrastructural challenges of CGT products and ways to bring the cost of goods down
• Why CGT is the therapy of the future... but why we must remember it’s not the only modality out there
• What the future looks like for CGT and exploring what happens when we have a treatment that can treat a lot more patients

Lung-I Cheng, Ph.D., is Vice President, Cell and Gene Therapy, leading AmerisourceBergen’s Cell and Gene Therapy (CGT) service line. In his role, he advances AmerisourceBergen’s CGT strategy with a focus on expanding the company’s portfolio of services to better support CGT innovators throughout the commercialization journey.

Before joining AmerisourceBergen, he spent a decade in biopharma, most recently serving as the head of Global Value & Access for Cell Therapies, Pipeline, and Business Development at Takeda.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.